CSL Seqirus has been awarded a new contract agreement to support the influenza pandemic preparedness plans of the Canadian government’s Public Health Agency of ...
Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, ...
The American Academy of Pediatrics generally recommends RSV immunization for infants under eight months old born during or entering their first RSV season if their mothers weren’t vaccinated during ...
Pharmaceutical Technology on MSN
Moderna’s dual Covid-flu vaccine poised for EMA approval on positive CHMP take
If approved, mCOMBRIAX would become the first combination Covid-flu jab to gain regulatory approval anywhere across the globe.
Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...
CLEVELAND — The FDA has reversed course and announced it will now review Moderna's mRNA flu vaccine application after initially declining to accept it earlier this month. The agency had raised ...
The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday. Last week, the FDA sent a missive to Moderna ...
Moderna said Wednesday the Food and Drug Administration changed course and will review an amended application for its new flu vaccine, a week after rejecting the original submission and fueling ...
The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date. In a regulatory turnaround, the FDA will now review Moderna’s seasonal mRNA flu vaccine ...
The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday. About two weeks ago, the FDA sent Moderna a ...
The U.S. Food and Drug Administration will review a messenger RNA (mRNA) flu vaccine for approval, according to its maker, Moderna. The decision is a dramatic U-turn for the agency, which, only about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results